Sunitinib Maleat

Indications & Dose:

Tyrosine kinase inhibitor , us after failure of imatinib.e for treatment of advance or metastatic renal cell carcinoma. Unresectable or metastatic malignant gastro-intestinal stromal tumours l

• BY MOUTH

50mg daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle; adjust dose in steps of 12.5mg according to tolerability; dose range 37.5—87.5mg daily

Contraindications:

breast-feeding

Side Effects:

also abdominal pain, anorexia, taste disturbance; hypertension, oedema; fatigue, dizziness, headache, paraesthesia; hypothyroidism; arthralgia, myalgia; lacrimation; epistaxis; skin and hair discoloration, hand-foot syndrome, and rash; gastro-intestinal perforation, pancreatitis, hepatic failure, and seizures reported 

Cautions:

monitor for signs and symptoms of congestive cardiac failure (consider interrupting or stopping treatment); susceptibility to QT-interval prolongation; hypertension; pregnancy

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: